Epidermal growth factor receptor tyrosine kinase inhibitors for non‐small cell lung cancer harboring uncommon EGFR mutations: Real‐world data from Taiwan

BACKGROUND: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) are the standard treatment for patients with non‐small cell lung cancer (NSCLC) harboring EGFR mutations. This study aimed to evaluate the efficacy of EGFR‐TKIs and prognostic factors for patients with NSCLC harborin...

Descripción completa

Detalles Bibliográficos
Autores principales: Chang, John Wen‐Cheng, Huang, Chen‐Yang, Fang, Yueh‐Fu, Chang, Ching‐Fu, Yang, Cheng‐Ta, Kuo, Chih‐Hsi Scott, Hsu, Ping‐Chih, Wu, Chiao‐En
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9807449/
https://www.ncbi.nlm.nih.gov/pubmed/36424878
http://dx.doi.org/10.1111/1759-7714.14537

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9807449/
https://www.ncbi.nlm.nih.gov/pubmed/36424878
http://dx.doi.org/10.1111/1759-7714.14537

Ejemplares similares